Trial Purpose

This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.

Learn More on



When speaking to your doctor, please have the trial identifier number available.

About The Study

Trial Phase Icon

Phase 3

Tests the medicine or vaccine in large groups of trial participants (from several hundred to several thousand). For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics, or physician offices.

Trial start Icon


  • Actual study start date 24 March 2022
  • Estimated primary completion date 8 May 2025
  • Estimated study completion date 7 June 2027


Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon


Small Cell Lung Carcinoma

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon



Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.